Grethe Nørskov Rasmussen
Corporate Officer/Principal bei FLUOGUIDE A/S
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Grethe Nørskov Rasmussen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| FLUOGUIDE A/S | Corporate Officer/Principal | 01.01.2019 | - |
Karriereverlauf von Grethe Nørskov Rasmussen
Ehemalige bekannte Positionen von Grethe Nørskov Rasmussen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ASCENDIS PHARMA A/S | Corporate Officer/Principal | 08.04.2010 | 01.01.2019 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | 01.01.2000 | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | 01.01.1989 | - |
Ausbildung von Grethe Nørskov Rasmussen
| Technical University of Denmark | Doctorate Degree |
Statistik
International
| Dänemark | 5 |
| Vereinigte Staaten | 2 |
Operativ
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ASCENDIS PHARMA A/S | Health Technology |
| NOVO NORDISK A/S | Health Technology |
| FLUOGUIDE A/S | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
